Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Dermatology Month in Review | November 2024
November's dermatology highlights include FDA approval of bimekizumab for HS, resubmissions for dupilumab and pz-cel, obesity's link to psoriasis, JNJ-2113's efficacy in psoriasis, stress's impact on skin aging, and factors affecting HS diagnostic wandering.
Vir Biotechnology EVP vanina de Verneuil sells $624 in stock
Vanina de Verneuil sold 76 Vir Biotechnology shares at $8.2201 each, holding 56,973 shares post-transaction. The company, with a $1.15B market cap, is undervalued and has strong financials. Vir's hepatitis treatments received orphan drug designation, and R&D expenses rose to $195M due to a Sanofi licensing agreement. The company plans to initiate a hepatitis delta virus registrational program in 2025.
Generic Pharmaceuticals Market to Hit $947.67 Bn by 2034
The generic pharmaceuticals market was valued at USD 424.98 billion in 2024 and is projected to reach USD 874.63 billion by 2033, driven by cost-effective medications, rising chronic disease prevalence, government support, and advancements in manufacturing technologies.
Respiratory Syncytial Virus Treatment Market 2034: Clinical
DelveInsight's report on the Respiratory Syncytial Virus (RSV) market forecasts trends and epidemiology in the U.S., EU4, UK, and Japan until 2034. Key companies include Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others. Promising therapies in development include Nirsevimab, RSVpreF Vaccine, and others. The market is expected to grow due to increasing incident cases and upcoming therapies, despite current treatment limitations.
Respiratory Syncytial Virus Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA
Respiratory syncytial virus (RSV) market report by DelveInsight covers epidemiology, market forecast, and key companies like Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others. Promising therapies include Nirsevimab, RSVpreF Vaccine, RSVpreF3 Vaccine, MVA-BN RSV Vaccine, Ad26.RSV.pre F Vaccine, mRNA-1345 Vaccine, NJ-53718678, Clesrovimab, EDP-938, MEDI8897, GS-5806, RV521, ALN-RSV01, and others.
Sarepta, Biotech's Regulatory Go-Getter, Signs Standout Rare Disease Deal
Sarepta Therapeutics, known for its focus on Duchenne muscular dystrophy, made a $500 million upfront deal with Arrowhead Pharmaceuticals, investing $325 million and up to $10 billion in milestones. The deal aims to diversify Sarepta's pipeline with RNA drugs and expand its portfolio into new disease areas. Despite Elevidys failing a confirmatory trial, Sarepta secured full FDA approval and a label expansion, generating $181 million in Q3. The deal reflects Sarepta's ability to secure regulatory success and diversify its portfolio, potentially offering new options for patients with rare diseases.
Obesity gene therapy enters Phase I testing
Resalis Therapeutics' Phase 1 trial tests RES-010, a miRNA-22 targeting obesity therapy, in healthy, overweight, and moderately obese volunteers. The trial aims to assess safety, tolerability, and efficacy, with data expected by mid-2026.
J&J Seeks FDA Approval for Tremfya for Psoriasis in Kids
Johnson & Johnson filed two sBLAs for Tremfya, seeking expanded use in pediatric patients with moderate-to-severe plaque psoriasis and active juvenile psoriatic arthritis. Tremfya, an IL-23 inhibitor, is already approved for adult patients with psoriasis and psoriatic arthritis. The filings are based on phase III studies and PK data. Tremfya sales grew 21.6% year-over-year to $2.7 billion in the first nine months of 2024. J&J expects Tremfya to reach $5 billion with approvals for inflammatory bowel disease conditions.
Sobi's strength in haematology to be showcased at ASH 2024
Sobi® and partners will present new data on haemophilia A, HLH, myelofibrosis, PNH, and ITP at the 66th ASH Annual Meeting in San Diego, December 7-10, 2024. Key presentations include long-term outcomes with ALTUVOCT® prophylaxis for haemophilia A and real-world effectiveness of Doptelet® in treating ITP.
Related Clinical Trials:
Drug Prices Negotiated by Medicare Still Higher Than Other Countries'
Negotiated prices for 10 Medicare drugs fell from initial net prices, with reductions ranging from 8% to 42%, but all except insulin aspart remained more expensive in the U.S. than in peer countries. The study highlights the need for continued assessment of future negotiation rounds, especially with potential inclusion of Part B drugs, to maximize savings.
© Copyright 2024. All Rights Reserved by MedPath